IMMUNIB trial (AIO-HEP-0218/ass): A single-arm, phase II study evaluating safety and efficacy of immunotherapy nivolumab in combination with lenvatinib in advanced-stage hepatocellular carcinoma (HCC).

被引：0
|
作者：
Vogel, Arndt
Siegler, Gabriele Margareta
Siebler, Jurgen
Lindig, Udo
Schultheiss, Michael
Mueller, Tobias
Simon, Henry
Joeckel, Christiane
Mueller, Daniel Wilhelm
Al-Batran, Salah-Eddin
Saborowski, Anna
De Toni, Enrico N.
机构：
[1] Hannover Med Sch, Klin Gastroenterol Hepatol & Endokrinol, Hannover, Germany
[2] Paracelsus Med Univ, Klinikum Nurnberg, Med Klin 5, Hamatol Onkol, Nurnberg, Germany
[3] Univ Klinikum Erlangen, Med Klin 1, Erlangen, Germany
[4] Univ Klinikum Jena, Klin Innere Med Hamtol Onckol 2, Jena, Germany
[5] Univ Klinikum Freiburg, Klin Innere Med 2, Freiburg, Germany
[6] Charite Univ Med Berlin CVK, Med Klin Gastroenterol Infektiol & Rheumatol, Berlin, Germany
[7] Rems Murr Klinikum Winnenden, Hamatol Onkol & Palliat Med, Winnenden, Germany
[8] Inst Klin Krebsforsch IKF Krankenhaus Nordwest, Frankfurt, Germany
[9] 2Krankenhaus Nordwest, Univ Canc Ctr Frankfurt, Frankfurt, Germany
[10] Hannover Med Sch, Klin Gastroenterol Hepatol & Endokrinol, Hannover, Germany
[11] LMU Munchen, Med Klin & Poliklin 2, Munich, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4107
引用
收藏
页数：1
相关论文
共 50 条
  • [1] IMMUNIB trial (AIO-HEP-0218/ass): A single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced hepatocellular carcinoma
    Vogel, A.
    Saborowski, A.
    Siegler, G. M.
    Siebler, J.
    Lindig, U.
    Schultheiss, M.
    Mueller, T.
    Simon, H.
    Joeckel, C.
    Muller, D. W.
    Al-Batran, S-E.
    De Toni, E.
    ANNALS OF ONCOLOGY, 2023, 34 : S598 - S598
  • [2] Safety analysis of the run-in phase (1st and 2nd cohort) of the IMMUNIB trial (AIO-HEP-0218/ass) - An open-label, single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced stage HCC
    Vogel, A.
    Mueller, D. W.
    De Toni, E.
    Siegler, G. M.
    Siebler, J.
    Lindig, U.
    Mueller, T.
    Schultheiss, M.
    Geissler, M.
    Krammer-Steiner, B.
    Reichart, A.
    Lammert, F.
    Prause, C.
    Walker, M.
    Al-Batran, S-E.
    Kosic, N.
    ANNALS OF ONCOLOGY, 2020, 31 : S691 - S691
  • [3] Safety Run-In Phase (SRP) cohorts 1 and 2 of the IMMUNIB trial (AIO-HEP-0218/ass): An open-label, single-arm phase II study evaluating safety and efficacy of immunotherapy with PD-L1/L2 inhibition (nivolumab) in combination with receptor tyrosine kinase inhibition (lenvatinib) in advanced stage hepatocellular carcinoma (HCC).
    Mueller, Daniel Wilhelm
    Siegler, Gabriele Margareta
    de Toni, Enrico
    Lindig, Udo
    Siebler, Jurgen
    Walker, Martin
    Al-Batran, Salah-Eddin
    Vogel, Arndt
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Efficacy and safety of the combination of envafolimab and lenvatinib in unresectable hepatocellular carcinoma: a single-arm, multicentre, exploratory phase II clinical study
    Jiang, Yi
    Su, Ke
    Li, Han
    Wang, Chenjie
    Wu, Zhenying
    Chen, Jiali
    Zhang, Zhiyao
    He, Kun
    Han, Yunwei
    INVESTIGATIONAL NEW DRUGS, 2025, 43 (01) : 18 - 29
  • [5] IMMUTACE: A biomarker-orientated phase II, single-arm, open-label AIO study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate-stage hepatocellular carcinoma (HCC; AIO-HEP-0217)-Updated efficacy results.
    Saborowski, Anna
    Waldschmidt, Dirk
    Hinrichs, Jan
    Ettrich, Thomas Jens
    Martens, Uwe Marc
    Mekolli, Ardian
    De Toni, Enrico N.
    Berg, Thomas
    Geissler, Michael
    Hausner, Guido
    Maenz, Martin
    Ehmer, Ursula
    Kirstein, Marta
    Vogel, Arndt
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] Efficacy and Safety of Bavituximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial
    Ali A. Mokdad
    Hao Zhu
    Muhammad S. Beg
    Yull Arriaga
    Jonathan E. Dowell
    Amit G. Singal
    Adam C. Yopp
    Targeted Oncology, 2019, 14 : 541 - 550
  • [7] Efficacy and Safety of Bavituximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial
    Mokdad, Ali A.
    Zhu, Hao
    Beg, Muhammad S.
    Arriaga, Yull
    Dowell, Jonathan E.
    Singal, Amit G.
    Yopp, Adam C.
    TARGETED ONCOLOGY, 2019, 14 (05) : 541 - 550
  • [8] Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: A multicenter, open-label, single-arm phase II study
    Srimuninnimit, Vichien
    Sriuranpong, Virote
    Suwanvecho, Suthida
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 (03) : 255 - 260
  • [9] Perioperative pembrolizumab and lenvatinib for resectable hepatocellular carcinoma: A single-arm, multi-center, phase II trial (NeoLEAP-HCC).
    Sun, Hui-Chuan
    Zhu, Xiao-Dong
    Wang, Kui
    Xue, Hui
    Yang, Ning
    Yang, Ying-Cheng
    Chen, Yong-Jun
    Ye, Feng
    Kuang, Ming
    Shen, Shun-Li
    Huang, Cheng
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] Camrelizumab combined with lenvatinib and RALOX-HAIC for hepatocellular carcinoma (HCC) in BCLC stage B and C: A prospective, single-arm, phase II trial (Cal Era study)
    Chen, Jinzhang
    Zang, Mengya
    Pang, Huajin
    Li, Chuanjiang
    Zhao, Jianbo
    Guo, Yabing
    Hou, Jinlin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345